Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
Subcutaneous tarlatamab is well tolerated and demonstrates preliminary antitumor activity in previously treated extensive-stage small cell lung cancer patients.
Subcutaneous administration of tarlatamab was well tolerated and showed preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer in a phase 1b study.
A subcutaneous formulation could reduce toxicity and simplify administration, potentially improving treatment options for extensive-stage small cell lung cancer.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells